UNSPSC 51111736: Cetuximab

This classification denotes a monoclonal antibody with the molecular formula C6484H10042N1732O2023S36, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PQX0D8J21J, more generally known as cetuximab. European Medicines Agency schedules cetuximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01178MIG. The term CETUXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 14, no. 3, 2000, list 44. Most nations schedule cetuximab under HS 30021091 and SITC 54163.

As of Q4 2014, CETUXIMAB remains the US FDA Preferred Term for this commodity. Cetuximab bears US NLM identifiers UMLS ID C0995188 and NCI Concept Code C1723. SMILES: CC(=O)NC1C(C(C(OC1N)CO)O)O.

UNSPSC 51111736 Cetuximab is a Commodity code for a branded monoclonal antibody pharmaceutical used in cancer treatment, but the recent state and local opportunities posted under this code show little activity aligned with the product itself. State and local health departments and counties do acquire specialty pharmaceuticals through piggyback and cooperative purchasing vehicles, typically sourced from pharmaceutical distributors and warehouse suppliers. The issuing bodies soliciting under this code include state health departments and county health authorities managing public health supply chains, though the recent posted opportunities reflect broader pharmaceutical procurement rather than cetuximab specifically.

The geographic activity visible in recent postings centers on Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC through the MMCAP Infuse consortium on August 28, 2026, under an Invitation for Bid (IFB 26482DPHPREPDB53392) for antibiotic tablets — Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg — with a 12-month initial term and two one-year renewal options. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial contract term and a one-year renewal option. The code shows limited recent solicitation volume tied to cetuximab procurement specifically; opportunities are scattered across state and local health purchasing rather than concentrated.